List view / Grid view
26 May 2016 | By Victoria White, Digital Content Producer
The FDA's EMDAC has recommended the approval of the NDA for the fixed-ratio combination of insulin glargine and lixisenatide...
25 May 2016 | By Victoria White, Digital Content Producer
NICE has published final guidance recommending three drugs for treating type 2 diabetes: canagliflozin, dapagliflozin and empagliflozin...
Stem cell therapy is currently utilised in medicine for its application in tissue repair and regenerative medicine. Unique characteristics of stem cells, such as self-renewal and differentiation, allow its function to be applicable for therapeutic purposes. Nanotechnology and cell microencapsulation have been researched and used as a means to protect…
For diabetes mellitus patients who treat themselves with insulin, the need to self-monitor blood glucose in order to establish their insulin dose is a major burden, and highlights the need to develop non-invasive glucose measurement technologies. Up until now, such non-invasive systems that also have adequate measurement performance under daily…
28 April 2016 | By Victoria White, Digital Content Producer
Adocia and Lilly have announced positive topline results from a Phase Ib trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro...
12 April 2016 | By Victoria White, Digital Content Producer
HinsBet is a rapid-acting formulation of recombinant human insulin using BioChaperone, which is designed to accelerate insulin absorption...
5 April 2016 | By Victoria White
In a three year trial, individuals treated with Saxenda lost more weight (6.1%) than those treated with placebo (1.9%)...
2 April 2016 | By Victoria White
Semaglutide significantly improved glycaemic control compared to placebo in adults with type 2 diabetes previously managed with diet and exercise alone...
4 March 2016 | By Victoria White
Victoza (liraglutide) was studied over a period of up to 5 years in more than 9,000 adults with type 2 diabetes at high risk of major adverse cardiovascular events...
3 March 2016 | By Victoria White
New findings show that Xultophy is cost-effective versus current insulin intensification treatment options for the treatment of people in the UK with type 2 diabetes...
23 February 2016 | By Victoria White
This NDA submission is based on data from two Phase 3 studies of insulin glargine and lixisenatide in patients with with type 2 diabetes...
18 February 2016 | By Victoria White
A new study has found that pioglitazone may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes...
29 January 2016 | By Victoria White
SWITCH 2 is the first of two trials comparing the safety and efficacy of Tresiba (insulin degludec) and insulin glargine in patients with type 2 diabetes...
26 January 2016 | By Victoria White
The FDA has accepted a sNDA for Jardiance (empagliflozin) based on cardiovascular risk reduction data from the EMPA-REG OUTCOME trial...
17 December 2015 | By Victoria White
The trial investigated the efficacy and safety of semaglutide compared with sitagliptin after 56 weeks of treatment in people with type 2 diabetes...
